Parnaparin
As of the edition of 20 October 2026, Parnaparin is an oligosaccharide: marketed; acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Oligosaccharide
- Brand name
- Fluxum
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Alfasigma
- Registered trials
- 1, 1 stopped early
- Disease areas
- Eye; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 1 |